Velan (VLN) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
9 Jul, 2026Executive summary
Bookings rose 63.0% year-over-year to $116.6 million, with sales up 22.8% to $98.7 million, reflecting robust performance across nuclear power, defense, and oil & gas sectors.
Net income improved to $0.1 million from a $2.1 million loss last year; cash flow from operations was $10.1 million for the quarter and $15 million for the first half.
Achieved highest order backlog in three years at $548.1 million, up $56.6 million since year start, with 72% deliverable within 12 months.
Secured major nuclear sector agreements, including a main services agreement with GEH SMR Technologies and a CAD 50 million, 10-year alliance with Bruce Power.
Diversified product portfolio and global reach contributed to growth, with strong sectoral contributions.
Financial highlights
Q2 sales totaled $98.7 million, up 22.8% year-over-year, with growth driven by increased shipments in Italy, France, and North America.
Gross profit was $26.7 million (27% of sales), up from $23.4 million; adjusted gross margin excluding non-recurring gain was 28.5%.
EBITDA rose to $5.1 million from $3 million; adjusted EBITDA last year was $3.3 million.
Non-recurring revenue gain of $5.2 million from a canceled agreement included in sales.
Cash and equivalents at $44.5 million, short-term investments $4.8 million, long-term debt $22.6 million.
Outlook and guidance
Maintains sales growth outlook for the fiscal year, supported by record backlog and strong bookings.
Expects continued momentum in the second half, with $395.9 million of orders deliverable within 12 months.
Latest events from Velan
- Geopolitical conflicts reduced sales and bookings, but backlog and liquidity remain strong.VLN
Q1 202714 Jul 2026 - Sales and backlog grew in 2026, with strong liquidity and major asset sales completed.VLN
Q4 202615 May 2026 - Bookings and backlog improved, supporting growth and cash flow focus for 2025.VLN
AGM 20243 Feb 2026 - Q1 sales up 14.5%, gross margin 30.7%, backlog $528.3M, and major nuclear deal signed.VLN
Q1 20253 Feb 2026 - Strong backlog, major asset sale, and ownership transition marked Q3 2026.VLN
Q3 202615 Jan 2026 - Q3 saw 18.1% sales growth, margin gains, and risk reduction from major divestitures.VLN
Q3 202510 Jan 2026 - Shareholders approved the $201.1 million sale of French subsidiaries to Framatome.VLN
EGM 202526 Dec 2025 - Sales and margins surged, with divestitures and a special dividend boosting future prospects.VLN
Q4 202524 Nov 2025 - 18.6% sales growth, margin gains, and record cash drive a higher dividend and strong outlook.VLN
Q1 202616 Nov 2025